CRISPR Therapeutics AG - Common Shares (CRSP)

The company had fallen out of investor favor; its recovery was impressive.

CRISPR's expanding pipeline could unlock significantly more value by 2031.

We'll know a little more about the company's prospects by the end of the year.

This year, the biotech stock has underperformed both the Nasdaq Biotechnology Index and the S&P 500.

Don't bet against Vertex Pharmaceuticals in cystic fibrosis.

The next six months may be decisive for the biotech.

Analysts remain optimistic that the market will view upcoming catalysts in a bullish light.

These stocks have market caps below $5 billion, but they could be much more valuable in the future.

This particular position isn't rooted solely in the science you've heard most about from the biopharma company so far.

Beam Therapeutics' growing pipeline could reward patient investors.

The company's innovative qualities may pay rich dividends down the road.

Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis franchise.

This new technology could one day significantly expand the market for gene-editing biotechs.

There's more to young biopharma companies than their numbers, but those numbers are still an important part of each investment thesis.

One has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your biotech bet.

One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their financials and risk profiles compare.

From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting financials and risk profiles.

Exploring some of the top bargains in a multi-trillion-dollar industry.

The opportunity is enormous, but uncertainty remains.

They have at least one thing in common: An exciting pipeline.

My strategy involves focusing on dividends, growth, and also taking on some calculated risk.

The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.

Its revolutionary CASGEVY treatment could be a sign of what's to come.

Eli Lilly's pipeline is an embarrassment of riches.

This little-discussed pipeline program could prove to be a big success.